# Kazumoto Iijima

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/kazumoto-iijima/

## Facts

| Field | Value |
| --- | --- |
| Citations | 15,324 |
| Field | Renal Diseases and Glomerulopathies |
| h-index | 62 |
| i10-index | 353 |
| Last Known Institution | Kobe Children's Hospital |
| OpenAlex ID | https://openalex.org/A5036822255 |
| ORCID iD | 0000-0003-0378-8174 |
| Works | 710 |

## Researcher papers

- [Idiopathic nephrotic syndrome in children](https://scholariq.org/papers/idiopathic-nephrotic-syndrome-in-children/)
- [Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial](https://scholariq.org/papers/rituximab-for-childhood-onset-complicated-frequently-relapsing-nephrotic/)
- [IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome](https://scholariq.org/papers/ipna-clinical-practice-recommendations-for-the-diagnosis-and-management-of-2/)
- [A review of clinical characteristics and genetic backgrounds in Alport syndrome](https://scholariq.org/papers/a-review-of-clinical-characteristics-and-genetic-backgrounds-in-alport-syndrome/)
- [Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children](https://scholariq.org/papers/single-dose-of-rituximab-for-refractory-steroid-dependent-nephrotic-syndrome-in/)
- [Rituximab in refractory nephrotic syndrome](https://scholariq.org/papers/rituximab-in-refractory-nephrotic-syndrome/)
- [Risk factors for cyclosporine-induced tubulointerstitial lesions in children with minimal change nephrotic syndrome](https://scholariq.org/papers/risk-factors-for-cyclosporine-induced-tubulointerstitial-lesions-in-children/)
- [Steroid Treatment for Severe Childhood IgA Nephropathy](https://scholariq.org/papers/steroid-treatment-for-severe-childhood-iga-nephropathy/)
- [Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome](https://scholariq.org/papers/rituximab-treatment-for-posttransplant-lymphoproliferative-disorder-ptld-induces/)
- [Genetic, Clinical, and Pathologic Backgrounds of Patients with Autosomal Dominant Alport Syndrome](https://scholariq.org/papers/genetic-clinical-and-pathologic-backgrounds-of-patients-with-autosomal-dominant/)
- [Genetic background, recent advances in molecular biology, and development of novel therapy in Alport syndrome](https://scholariq.org/papers/genetic-background-recent-advances-in-molecular-biology-and-development-of-novel/)

## Researcher topics

- [Renal Diseases and Glomerulopathies](https://scholariq.org/topics/renal-diseases-and-glomerulopathies/)
- [Renal and related cancers](https://scholariq.org/topics/renal-and-related-cancers/)
- [Cell Adhesion Molecules Research](https://scholariq.org/topics/cell-adhesion-molecules-research/)
- [Vasculitis and related conditions](https://scholariq.org/topics/vasculitis-and-related-conditions/)
- [Ion Transport and Channel Regulation](https://scholariq.org/topics/ion-transport-and-channel-regulation/)

## Researcher university

- [Kobe Children's Hospital](https://scholariq.org/institutions/kobe-children-s-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.